Xin Grevers1, Anne Grundy1, Abbey E Poirier1, Farah Khandwala1, Matthew Feldman1, Christine M Friedenreich1, Darren R Brenner1. 1. Department of Cancer Epidemiology and Prevention Research (Grevers, Grundy, Poirier, Khandwala, Feldman, Friedenreich, Brenner), CancerControl Alberta, Alberta Health Services; Department of Oncology and Department of Community Health Sciences (Friedenreich, Brenner), Cumming School of Medicine, University of Calgary, Calgary, Alta.
Abstract
BACKGROUND: Hormonal contraceptives and hormone replacement therapies are classified as carcinogenic to humans (group 1) by the International Agency for Research on Cancer. We sought to estimate the proportion and total number of cancers attributable to the use of oral contraceptives and hormone therapy in Alberta in 2012. METHODS: Population attributable risks were used to estimate the proportion of attributable cases for each associated cancer site. Relative risk estimates were obtained from the most relevant and recent epidemiologic literature. Prevalences of the use of oral contraceptives and hormone therapy in Alberta were collected from Alberta's Tomorrow Project. Specific cancer incidence data were obtained from the Alberta Cancer Registry for the year 2012. RESULTS: Overall, 6.3% of breast cancers (n = 135) diagnosed in Alberta in 2012 were estimated to be attributable to the use of oral contraceptives, and the exposure potentially prevented about 57.3% of endometrial cancers (n = 276) and 29.1% of ovarian cancers (n = 52). About 15.5% of breast cancers (n = 258) and 8.9% of ovarian cancers (n = 13) were estimated to be attributable to the use of hormone therapy, whereas 11.3% of endometrial cancers (n = 48) were possibly prevented by the exposure. INTERPRETATION: Based on our estimates, oral contraceptive use resulted in a net protective effect among the cancer sites studied, thus reducing the cancer burden in Alberta in 2012. The use of hormone therapy was estimated to increase the cancer burden in the province, therefore the risk and benefit of hormone therapy should be carefully considered before use.
BACKGROUND: Hormonal contraceptives and hormone replacement therapies are classified as carcinogenic to humans (group 1) by the International Agency for Research on Cancer. We sought to estimate the proportion and total number of cancers attributable to the use of oral contraceptives and hormone therapy in Alberta in 2012. METHODS: Population attributable risks were used to estimate the proportion of attributable cases for each associated cancer site. Relative risk estimates were obtained from the most relevant and recent epidemiologic literature. Prevalences of the use of oral contraceptives and hormone therapy in Alberta were collected from Alberta's Tomorrow Project. Specific cancer incidence data were obtained from the Alberta Cancer Registry for the year 2012. RESULTS: Overall, 6.3% of breast cancers (n = 135) diagnosed in Alberta in 2012 were estimated to be attributable to the use of oral contraceptives, and the exposure potentially prevented about 57.3% of endometrial cancers (n = 276) and 29.1% of ovarian cancers (n = 52). About 15.5% of breast cancers (n = 258) and 8.9% of ovarian cancers (n = 13) were estimated to be attributable to the use of hormone therapy, whereas 11.3% of endometrial cancers (n = 48) were possibly prevented by the exposure. INTERPRETATION: Based on our estimates, oral contraceptive use resulted in a net protective effect among the cancer sites studied, thus reducing the cancer burden in Alberta in 2012. The use of hormone therapy was estimated to increase the cancer burden in the province, therefore the risk and benefit of hormone therapy should be carefully considered before use.
Authors: Linda S Cook; Andy C Y Leung; Kenneth Swenerton; Richard P Gallagher; Anthony Magliocco; Helen Steed; Martin Koebel; Jill Nation; Sima Eshragh; Angela Brooks-Wilson; Nhu D Le Journal: Gynecol Oncol Date: 2015-12-12 Impact factor: 5.482
Authors: Laura J Havrilesky; Patricia G Moorman; William J Lowery; Jennifer M Gierisch; Remy R Coeytaux; Rachel Peragallo Urrutia; Michaela Dinan; Amanda J McBroom; Vic Hasselblad; Gillian D Sanders; Evan R Myers Journal: Obstet Gynecol Date: 2013-07 Impact factor: 7.661
Authors: I-Min Lee; Eric J Shiroma; Felipe Lobelo; Pekka Puska; Steven N Blair; Peter T Katzmarzyk Journal: Lancet Date: 2012-07-21 Impact factor: 79.321
Authors: Darren R Brenner; Abbey E Poirier; Stephen D Walter; Will D King; Eduardo L Franco; Paul A Demers; Paul J Villeneuve; Yibing Ruan; Farah Khandwala; Xin Grevers; Robert Nuttall; Leah Smith; Prithwish De; Karena Volesky; Dylan O'Sullivan; Perry Hystad; Christine M Friedenreich Journal: BMJ Open Date: 2018-08-01 Impact factor: 2.692
Authors: Lieske H Schrijver; Thea M Mooij; Anouk Pijpe; Gabe S Sonke; Marian J E Mourits; Nadine Andrieu; Antonis C Antoniou; Douglas F Easton; Christoph Engel; David Goldgar; Esther M John; Karin Kast; Roger L Milne; Håkan Olsson; Kelly-Anne Phillips; Mary Beth Terry; John L Hopper; Flora E van Leeuwen; Matti A Rookus Journal: J Natl Cancer Inst Date: 2022-04-11 Impact factor: 13.506